Noxxon Pharma AG has become the latest company to reach an agreement with Merck & Co Inc to test a portfolio drug with Keytruda (pembrolizumab), the US company’s immune checkpoint inhibitor. ---Subscribe to MedNous to access this article--- Clinical Research Company News Finance, Grants, Deals
